Genomic cancer panel market seen topping $16 billion by 2030

By AI, Created 5:00 PM UTC, May 18, 2026, /AGP/ – The Business Research Company projects the genomic cancer panel and profiling market will exceed $16 billion by 2030, led by North America and the U.S. The report points to precision oncology, rising cancer cases and companion diagnostics as the main growth drivers.

Why it matters: - The genomic cancer panel and profiling market is moving deeper into routine cancer care as precision oncology, companion diagnostics and faster sequencing tools expand. - The report pegs the market at more than $16 billion by 2030, signaling meaningful demand for diagnostic testing tied to targeted therapies and cancer monitoring. - North America and the U.S. are expected to anchor much of that growth, shaping where investment, lab capacity and clinical adoption concentrate.

What happened: - The Business Research Company published a genomic cancer panel and profiling market report on May 12, 2026. - The report forecasts the market will surpass $16 billion by 2030. - The market is expected to grow at a 9% CAGR through 2030. - North America is projected to be the largest region in 2030, at $6.1 billion. - The U.S. is projected to be the largest country in 2030, at $5.6 billion. - The report says solid tissue testing will be the largest segment by tissue testing, reaching $11 billion and accounting for 67% of the market in 2030. - The report also breaks the market into NGS, PCR, FISH, IHC and other technologies; single-gene and multi-gene panels; clinical and research applications; and hospitals, research and academic institutes, clinical and diagnostic laboratories, and other end users. - Request a free sample of the report - Access the detailed market report

The details: - North America is forecast to grow from $4.1 billion in 2025 to $6.1 billion in 2030, a CAGR of 8%. - The report links North American growth to precision oncology adoption, genomic profiling in routine diagnostics, advanced healthcare infrastructure, sequencing facilities, biotech-research partnerships and bioinformatics tools. - The U.S. market is forecast to rise from $3.8 billion in 2025 to $5.6 billion in 2030, also at an 8% CAGR. - The report ties U.S. growth to personalized medicine, companion diagnostics, reimbursement coverage, biomarker-focused clinical trials and liquid biopsy adoption. - Solid tissue testing is supported by its role in definitive diagnosis, mutation detection, broad oncology acceptance, tumor profiling demand and better sample-prep and sequencing accuracy. - Solid tissue testing is projected to grow by $4 billion from 2025 to 2030. - Liquid tissue testing is projected to grow by $2 billion over the same period. - Together, solid tissue testing and liquid tissue testing are expected to add more than $6 billion in market value by 2030. - The report says the genomic cancer panel and profiling market represents about 7% of the parent medical laboratory services market, which is expected to reach $237 billion by 2030. - The market is estimated to represent nearly 0.1% of the broader healthcare services industry, projected at $11,335 billion by 2030.

Between the lines: - The forecast suggests genomic testing is shifting from specialized oncology use toward broader clinical workflows. - Solid tissue testing still dominates, but liquid biopsy and other less invasive approaches are gaining ground as cancer detection and monitoring move earlier and more frequently. - The growth drivers point to a market shaped less by consumer demand than by clinical utility, reimbursement and drug-development pipelines. - The regional concentration in North America and the U.S. indicates that infrastructure and regulatory support remain key advantages in advanced cancer diagnostics.

What’s next: - The fastest growth is likely to come from institutions that can combine sequencing, interpretation software and oncology decision support. - Companion diagnostics should keep expanding as targeted therapy pipelines mature and more biomarker-linked treatments reach patients. - Liquid tissue testing may take a larger role if non-invasive detection continues to gain reimbursement and clinical acceptance. - The report expects precision oncology adoption, rising cancer incidence and companion diagnostics to keep driving the market through 2030.

The bottom line: - Genomic cancer profiling is becoming a bigger part of cancer diagnosis and treatment selection, with North America and solid tissue testing set to capture much of the near-term value.